Genelux provides Phase 3 enrollment timeline for Olvi-Vec and cash runway into Q1 2026

GENELUX Corp

Enrollment for Phase 3 trial of Olvi-Vec in platinum-resistant/refractory ovarian cancer expected to complete mid-2024 with 11-month follow-up.
Initial interim data for Phase 2 trial of Olvi-Vec in recurrent non-small-cell lung cancer expected as early as mid-2024.
Cash operating runway expected to extend into first quarter of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.